{
  "articles": [
    {
      "path": "appendix.html",
      "title": "Appendix of requested variables",
      "author": [
        {
          "name": "Luke W. Johnston",
          "url": "https://lukewjohnston.com/"
        }
      ],
      "contents": "\n\nContents\nProjekttitel og -nr\nPopulations afgrænsning(er)\nList of registers and variables from DST\nList of registers and variables from external sources\nDet Nationale Diabetesregister\nLabka\nList of requested ICD-8 and -10 codes\nJustification for requested disease codes\nList of requested ATC codes\n\nDanmarks Statistik, Forskningsservice September 03, 2021\nGenerel Forskningsservice\nProjektnr. <xxxxxx\nLuke W. Johnston, Steno Diabetes Center Aarhus\nProjekttitel og -nr\nInterplay between diabetes and intergenerational transmission of health determinants over the life course\nPopulations afgrænsning(er)\n\nIn order to identify familial relations through individuals’ life course trajectory, the population requested covers all individuals, who live or lived in Denmark from 1 January 1970 to 31 December 2020 (~8.5 million people). Key requirements are:\nAll index individuals born or who migrated into Denmark on or after 1970-01-01.\nAll family members of the index individuals, including parents, siblings, spouses, and children.\nList of registers and variables from DST\n\nGrundregisternavn: Arbejdsklassifikationsmodulet (AKM)\nGrundregisternavn: Befolkningen (BEF)\nGrundregisternavn: CPR Status (CPST)\nGrundregisternavn: Døde i Danmark (DOD)\nGrundregisternavn: Dødfødte ud fra LPR (LPRMFRDF)\nGrundregisternavn: Dødsårsagsregister (DODSAASG)\nGrundregisternavn: Dødsårssagsregistret (DODSAARS)\nGrundregisternavn: Familieindkomster (FAIK)\nGrundregisternavn: Fertilitet - børn (FTBARN)\nGrundregisternavn: Fertilitet - forælder (FTFORAEL)\nGrundregisternavn: Fertilitetsdatabasen børn (FTDB)\nGrundregisternavn: Fertilitetsdatabasen paritetsfil kvinder (FTDK)\nGrundregisternavn: Fertilitetsdatabasen paritetsfil mænd (FTDM)\nGrundregisternavn: Historiske vandringer (VNDS)\nGrundregisternavn: Husstande og familier (FAIN)\nGrundregisternavn: IDA ansættelser (IDAN)\nGrundregisternavn: IDA persondata (IDAP)\nGrundregisternavn: Indkomst (IND)\nGrundregisternavn: Indvandrere og Efterkommere (IEPE)\nGrundregisternavn: Lægemiddeldatabasen (LMDB)\nGrundregisternavn: Landspatientregistret - administrative oplysninger (LPR_ADM)\nGrundregisternavn: Landspatientregistret - ambulante besøgsdatoer (LPR_BES)\nGrundregisternavn: Landspatientregistret - diagnoser (LPR_DIAG)\nGrundregisternavn: Landspatientregistret - operationer (LPR_SKSOPR)\nGrundregisternavn: Landspatientregistret - operationer efter ICD8 klassifikationen (LPR_OPR)\nGrundregisternavn: Landspatientregistret - undersøgelser og behandlinger (LPR_SKSUBE)\nGrundregisternavn: Levendefødte ud fra LPR (LPRMFRLF)\nGrundregisternavn: Sammenhængende socialstatistik (SHSS)\nGrundregisternavn: Sammenhængende socialstatistik nettovarigheder (SSNV)\nGrundregisternavn: Sygesikring (6-cifret) (SSSY)\nGrundregisternavn: Sygesikring (6-cifret) (SYSI)\nGrundregisternavn: Uddannelser (BUE) (UDDA)\n\nList of registers and variables from external sources\nDet Nationale Diabetesregister\n\n.tabwid table{\n  border-collapse:collapse;\n  line-height:1;\n  margin-left:auto;\n  margin-right:auto;\n  border-width: 0;\n  display: table;\n  margin-top: 1.275em;\n  margin-bottom: 1.275em;\n  border-spacing: 0;\n  border-color: transparent;\n}\n.tabwid_left table{\n  margin-left:0;\n}\n.tabwid_right table{\n  margin-right:0;\n}\n.tabwid td {\n    padding: 0;\n}\n.tabwid a {\n  text-decoration: none;\n}\n.tabwid thead {\n    background-color: transparent;\n}\n.tabwid tfoot {\n    background-color: transparent;\n}\n.tabwid table tr {\nbackground-color: transparent;\n}\n.cl-2fd720a8{border-collapse:collapse;}.cl-2fcdd552{font-family:'Times New Roman';font-size:12pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(255, 255, 255, 1.00);background-color:transparent;}.cl-2fcdd57a{font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-2fcdec4a{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-2fcdec72{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-2fce48ac{width:108pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-2fce48f2{width:216pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-2fce4906{width:108pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-2fce4910{width:216pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-2fce4924{width:108pt;background-color:rgba(79, 129, 189, 1.00);vertical-align: top;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-2fce4938{width:216pt;background-color:rgba(79, 129, 189, 1.00);vertical-align: top;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}TabelVariablerBeskrivelseÅrt_diabetesd_blod2i5Hvis personen opfylder inklusionskriteriet ”Blod2i5” vil variablen indeholde datoen for opfyldelse af kriteriet. Ellers vil variablen være tom.Kriteriet blod2i5 er opfyldt, når man over en femårig periode har haft mindst to blodsukkermålinger per år. Dette kriterium følger kalenderåret. Datoen for opfyldelse er datoen for den anden blodsukkermåling det femte år.1990-Latestt_diabetesd_blod5i1Regelmæssige målinger af blodsukker er en stærk indikation af, at den pågældende person har diabetes. Det er derfor et af flere inklusionskriterier i NDR.Kriteriet blod5i1 er opfyldt for en person, der er bosat i Danmark og indenfor en periode af 365 dage har fået foretaget mindst 5 blodsukkermålinger. Datoen for opfyldelse af kriteriet er datoen for den femte af disse blodsukkermålinger.Hvis personen opfylder inklusionskriteriet ”Blod5i1” vil variablen indeholde datoen for opfyldelse af kriteriet. Ellers vil variablen være tom.Eneste undtagelse er kvinder med indikationer på gestationel diabetes, som kan opstå i forbindelse med graviditet. Da gestitionel diabetes er af forbigående karakter, skal kvinder med denne diagnose (ICD8-kode: 63474, ICD10-kode: DO244) ikke inkluderes i registeret. Derfor ses der bort fra alle registreringer af indikatorer registreringer et år fra og med indlæggelsesdatoen for en kontakt med gestationel diabetes.Øvrige inklusionskriterier fremgår af variablene d_blod2i5, d_fodt, d_lpr, d_oad og d_ins.1990-Latestt_diabetesd_dodsdtoVariablen angiver dødsdatoen for en person inkluderet i registeret.Hvis personen ikke er død inden for den aktuelle periodegrænse, vil variablen være tom.1990-Latestt_diabetesd_fodtHvis en person har modtaget ydelsen ”Fodterapi for Sukkersygepatienter”, er det efter reglerne sket efter lægefaglig vurdering og vedkommende må derfor regnes som diabetespatient og kan dermed inkluderes i NDR.Kriteriet ”fodterapi” er opfyldt for en person, der er bosat i Danmark og har haft mindst én ydelse af typen ”Fodterapi for Sukkersygepatienter”. Datoen for opfyldelse af kriteriet er datoen for den første af disse ydelser.Hvis personen opfylder inklusionskriteriet ”Fodt” vil variablen indeholde datoen for opfyldelse af kriteriet. Ellers vil variablen være tom.Eneste undtagelse er kvinder med indikationer på gestationel diabetes, som kan opstå i forbindelse med graviditet. Da gestitionel diabetes er af forbigående karakter, skal kvinder med denne diagnose (ICD8-kode: 63474, ICD10-kode: DO244) ikke inkluderes i registeret. Derfor ses der bort fra alle registreringer af indikatorer registreringer et år fra og med indlæggelsesdatoen for en kontakt med gestationel diabetes.Øvrige inklusionskriterier fremgår af variablene d_blod5i1, d_blod2i5, d_lpr, d_oad og d_ins. En person kan med tiden opfylde flere inklusionskriterier.1990-Latestt_diabetesd_inkldtoVariablen angiver den dato, hvor personen inkluderes i registeret. Dette sker første gang vedkommende opfylder en af de i alt 6 inklusionskriterier ”blod5i1”, ”blod2i5”, ”fodterapi”, ”lpr”, ”oad” og ”ins”.Variablen er central i registeret og benyttes fx ved beregninger prævalens og incidens.Datoen for evt. opfyldelse af hver af de 6 inklusionskriterier, er indeholdt i variablene d_blod5i1, d_blod2i5, d_fodt, d_lpr, d_oad og d_ins.Selvom data fra ovenstående kilder tidligst indkluderes fra 1990 kan personer godt optræde med en inklusionsdato før 1990. Dette skyldes at inklusionen af f.eks. LPR-data fra 1990 svarer til kontakter med en udskrivningsdato i 1990. Disse kan godt have en indskrivningsdato før 1990, og det er denne indskrivningsdato, der anvendes til at angive inklusionsdato.1990-Latestt_diabetesd_insHvis en person regelmæssigt indløser en recept på insulin antages det, at vedkommende med stor sandsynlighed er diabetiker.Inklusionskriteriet ”INS” er opfyldt for en person, der er bosat i Danmark og inden for en periode af 6 måneder har indløst 2 recepter på insulin (ATC-kode A10A*). Datoen for opfyldelse af kriteriet er datoen for den anden af de to receptindløsninger.Hvis personen opfylder inklusionskriteriet ”INS” vil variablen indeholde datoen for opfyldelse af kriteriet. Ellers vil variablen være tom.Eneste undtagelse er kvinder med indikationer på gestationel diabetes, som kan opstå i forbindelse med graviditet. Da gestitionel diabetes er af forbigående karakter, skal kvinder med denne diagnose (ICD8-kode: 63474, ICD10-kode: DO244) ikke inkluderes i registeret. Derfor ses der bort fra alle registreringer af indikatorer registreringer et år fra og med indlæggelsesdatoen for en kontakt med gestationel diabetes.Øvrige inklusionskriterier fremgår af variablene d_blod2i5, d_blod5i1, d_fodt, d_lpr, og d_oad .1990-Latestt_diabetesd_insHvis en person regelmæssigt indløser en recept på insulin antages det, at vedkommende med stor sandsynlighed er diabetiker.Inklusionskriteriet ”INS” er opfyldt for en person, der er bosat i Danmark og inden for en periode af 6 måneder har indløst 2 recepter på insulin (ATC-kode A10A*). Datoen for opfyldelse af kriteriet er datoen for den anden af de to receptindløsninger.Hvis personen opfylder inklusionskriteriet ”INS” vil variablen indeholde datoen for opfyldelse af kriteriet. Ellers vil variablen være tom.Eneste undtagelse er kvinder med indikationer på gestationel diabetes, som kan opstå i forbindelse med graviditet. Da gestitionel diabetes er af forbigående karakter, skal kvinder med denne diagnose (ICD8-kode: 63474, ICD10-kode: DO244) ikke inkluderes i registeret. Derfor ses der bort fra alle registreringer af indikatorer registreringer et år fra og med indlæggelsesdatoen for en kontakt med gestationel diabetes.Øvrige inklusionskriterier fremgår af variablene d_blod2i5, d_blod5i1, d_fodt, d_lpr, og d_oad .1994-Latestt_diabetesd_lprHvis en person er registreret i sygehusvæsenet med en diagnose inden for området diabetes, er personen med meget stor sandsynlighed diabetiker og kan inkluderes i NDR. Dermed opfylder personen inklusionskriteriet ”LPR”, som er det eneste inklusionskriterium, der er baseret på konkrete diagnoser.Kriteriet ”LPR” er opfyldt for en person, der er bosat i Danmark og i Landspatientregisteret er registreret 1 gang med en af nedenstående diagnosekoder, som enten aktions- eller bidiagnose.ICD8-koder: 249*, 250*. SKS-koder (baseret på ICD10): DE10*, DE11*, DE12*, DE13*, DE14*, DO24*, DH360*.Datoen for opfyldelse af kriteriet er indskrivningsdatoen for den første kontakt, hvor en sådan registrering er foregået. Det betydet at selvom data fra LPR først indkluderes fra 1990 kan personer godt optræde med en inklusionsdato før 1990. Dette skyldes at LPR-data fra 1990 svarer til kontakter med en udskrivningsdato i 1990, og disse kan godt have en indskrivningsdato før 1990.Hvis personen opfylder inklusionskriteriet ”LPR” vil variablen indeholde datoen for opfyldelse af kriteriet. Ellers vil variablen være tom.Eneste undtagelse er kvinder med indikationer på gestationel diabetes, som kan opstå i forbindelse med graviditet. Da gestitionel diabetes er af forbigående karakter, skal kvinder med denne diagnose (ICD8-kode: 63474, ICD10-kode: DO244) ikke inkluderes i registeret. Derfor ses der bort fra alle registreringer af indikatorer registreringer et år fra og med indlæggelsesdatoen for en kontakt med gestationel diabetes.Øvrige inklusionskriterier fremgår af variablene d_blod5i1, d_blod2i5, d_fodt, d_lpr, d_oad og d_ins. En person kan med tiden opfylde flere inklusionskriterier.1990-Latestt_diabetesd_oadHvis en person regelmæssigt indløser en recept på oral antidiabetika (tabletbehandling) antages det, at vedkommende med stor sandsynlighed er diabetiker.Inklusionskriteriet ”OAD” ” er opfyldt for en person, der er bosat i Danmark og inden for en periode af 6 måneder har indløst 2 recepter på oral antidiabetika (ATC-kode A10B*). Datoen for opfyldelse af kriteriet er datoen for den anden af de to receptindløsninger.Hvis personen opfylder inklusionskriteriet ”OAD” vil variablen indeholde datoen for opfyldelse af kriteriet. Ellers vil variablen være tom.Der er dog to undtagelser: 1.Kvinder med indikationer på gestationel diabetes, som kan opstå i forbindelse med graviditet. Da gestitionel diabetes er af forbigående karakter, skal kvinder med denne diagnose (ICD8-kode: 63474, ICD10-kode: DO244) ikke inkluderes i registeret. Derfor ses der bort fra alle registreringer af indikatorer registreringer et år fra og med indlæggelsesdatoen for en kontakt med gestationel diabetes.2.Der ses ligeledes bort fra indløsning af recepter af antidiabetika for kvinder i alderen 20-39. Dette skyldes, at kvinder med PCO (polycystisk ovarie syndrom) i stigende omfang behandles med peroralt antidiabetikum (tabletbehandling). Flertallet af disse kvinder har ikke diabetes og skal derfor ikke indgå i det Nationale Diabetesregister. For at undgå fejlagtigt at inkludere en gruppe uden diabetes i registeret, er det derfor valgt at ekskludere alle kvinder med tabletbehandlet diabetes i alderen 20-39 år, og som alene opfylder kriteriet OAD.Øvrige inklusionskriterier fremgår af variablene d_blod2i5, d_blod5i1, d_fodt, d_lpr, og d_ins .1990-Latestt_diabetesd_oadHvis en person regelmæssigt indløser en recept på oral antidiabetika (tabletbehandling) antages det, at vedkommende med stor sandsynlighed er diabetiker.Inklusionskriteriet ”OAD” ” er opfyldt for en person, der er bosat i Danmark og inden for en periode af 6 måneder har indløst 2 recepter på oral antidiabetika (ATC-kode A10B*). Datoen for opfyldelse af kriteriet er datoen for den anden af de to receptindløsninger.Hvis personen opfylder inklusionskriteriet ”OAD” vil variablen indeholde datoen for opfyldelse af kriteriet. Ellers vil variablen være tom.Der er dog to undtagelser: 1.Kvinder med indikationer på gestationel diabetes, som kan opstå i forbindelse med graviditet. Da gestitionel diabetes er af forbigående karakter, skal kvinder med denne diagnose (ICD8-kode: 63474, ICD10-kode: DO244) ikke inkluderes i registeret. Derfor ses der bort fra alle registreringer af indikatorer registreringer et år fra og med indlæggelsesdatoen for en kontakt med gestationel diabetes.2.Der ses ligeledes bort fra indløsning af recepter af antidiabetika for kvinder i alderen 20-39. Dette skyldes, at kvinder med PCO (polycystisk ovarie syndrom) i stigende omfang behandles med peroralt antidiabetikum (tabletbehandling). Flertallet af disse kvinder har ikke diabetes og skal derfor ikke indgå i det Nationale Diabetesregister. For at undgå fejlagtigt at inkludere en gruppe uden diabetes i registeret, er det derfor valgt at ekskludere alle kvinder med tabletbehandlet diabetes i alderen 20-39 år, og som alene opfylder kriteriet OAD.Øvrige inklusionskriterier fremgår af variablene d_blod2i5, d_blod5i1, d_fodt, d_lpr, og d_ins .1994-Latestt_diabetesv_cprVariablen angiver cpr-nummer for personer inkluderet i NDR.Dan variablen angiver enkeltindivider, er den central i alle typer opgørelser og beregninger.Variablen er desuden nøglevariabel ved kobling mellem tabellerne td_diabetes og dt_bopael.1990-Latestt_diabetesv_inklaarsagVariablen angiver hvilket af de i alt 6 inklusionskriterier personen opfyldte, da vedkommende blev inkluderet i NDR. Inklusionen i NDR sker første gang vedkommende opfylder en af de i alt 6 inklusionskriterier ”blod5i1”, ”blod2i5”, ”fodterapi”, ”lpr”, ”oad” og ”ins”. Datoen for dette er værdien af variablen d_inkldto.De 6 inklusionskriterier er nærmere beskrevet i den overordnede beskrivelse af NDR og hver især i beskrivelsen af variablene d_blod5i1, d_blod2i5, d_fodt, d_lpr, d_oad og d_ins.1990-Latest\n\nvar dest = document.getElementById(\"891b7791-5fdf-4cfb-8da7-0fe94de94a09\");\nvar template = document.getElementById(\"c70668ac-b045-4db8-97bf-29c53e3bb034\");\nvar caption = template.content.querySelector(\"caption\");\nif(caption) {\n  caption.style.cssText = \"display:block;text-align:center;\";\n  var newcapt = document.createElement(\"p\");\n  newcapt.appendChild(caption)\n  dest.parentNode.insertBefore(newcapt, dest.previousSibling);\n}\nvar fantome = dest.attachShadow({mode: 'open'});\nvar templateContent = template.content;\nfantome.appendChild(templateContent);\n\nCancerregisteret\nDBDD\nDVDD\nIVF\nLandsdækkende kliniske kvalitetsdatabase for screening af diabetisk retinopati og maculopati (DiaBase)\nLPR_PSYK\n\nLabka\nFor alle individer i databasen ønskes der laboratorie udtræk af følgene NPU/DNK-koder så langt tilbage i tiden som muligt.\n\n\n.tabwid table{\n  border-collapse:collapse;\n  line-height:1;\n  margin-left:auto;\n  margin-right:auto;\n  border-width: 0;\n  display: table;\n  margin-top: 1.275em;\n  margin-bottom: 1.275em;\n  border-spacing: 0;\n  border-color: transparent;\n}\n.tabwid_left table{\n  margin-left:0;\n}\n.tabwid_right table{\n  margin-right:0;\n}\n.tabwid td {\n    padding: 0;\n}\n.tabwid a {\n  text-decoration: none;\n}\n.tabwid thead {\n    background-color: transparent;\n}\n.tabwid tfoot {\n    background-color: transparent;\n}\n.tabwid table tr {\nbackground-color: transparent;\n}\n.cl-3049beb0{border-collapse:collapse;}.cl-3040229c{font-family:'Times New Roman';font-size:12pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(255, 255, 255, 1.00);background-color:transparent;}.cl-304022ce{font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-30403a3e{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-30403a66{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-3040d214{width:162pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-3040d25a{width:162pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-3040d26e{width:162pt;background-color:rgba(79, 129, 189, 1.00);vertical-align: top;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}KomponentKodeEnhedP- Alanintransaminase [ALAT]NPU19651 (katalytisk akt konc. IFCC2002)U/LNPU01121 (katalytisk akt konc. 37 gr. C)Ukat/LNPU19981 (katalytisk akt konc. IFCC2002)Ukat/LDNK05051 (erstattet af NPU 53495)U/LNPU53495 (katalytisk akt konc. 37 gr. C)U/LP- AlbuminNPU19673 (massek.(proc)g/LNPU01132 (stofkonc)umol/LDNK05449 stofk. (kolorim.)umol/LDNK05001 (erstattet af NPU19673)g/LU-alb/crea ratioNPU19661 (masseratio)Ratio (10-3)DNK05289 (erstattet af: NPU19661)Ratio (10-3)NPU28842 (massekoeficient)g/molNPU03918 (stofratio)Ratio (10-3)P- Basisk fosfataseNPU27783 (katalytisk aktivitets konc, 37 gr. C)U/Lp-CRPNPU19748mg/LNPU01422IU/LNPU01423nmol/LDNK05027mg/LeGFRDNK35302 (CKD-EPI krea)mL/min Per 1,73m2DNK35131 (nyre)mL/min Per 1,73m2DNK30301 (CKD-EPI CysC)mL/min Per 1,73m2DNK35303 CKiD-CysCmL/min Per 1,73m2DNK35304 (CKiD-Bedside)mL/min Per 1,73m2GFRNPU19597 chrom.EDTAmL/min Per 1,73m2NPU28271 chrom.EDTAmL/min Per 1,73m2NPU10295 chrom.EDTAmL/min Per 1,73m2P- GlukoseNPU02192P (vB; fPt)- Glukose (diag.)DNK35842 (fastende patient)mmol/Lp-glucose 0 minNPU04173 (0 min i belastning)mmol/Lp-glucose 30 minNPU04174 (30 min i belastningstest)mmol/Lp-glucose 120 minNPU04177 (120 min i belastning)mmol/LPt- Glucose-belastning gruppeNPU14915Indeholder alle målene fra en glukose tolerance test inkl. De tre ovenstående ved 0,30 og 120 minB- HæmoglobinNPU02319mmol/LHb (B)- Hæmoglobin A1c (IFCC)NPU27300 (IFCC)mmol/molNPU27412 (genn. HbA1cmmol/LDNK35249 (prot glycolering, gruppe)ratioNPU03835 (glycoleret hæmoglobin)ratioP- KaliumNPU03230mmol/LP- KolesterolNPU01566mmol/LNPU18412 (fPt)mmol/LNPU01549 (non-ester)mmol/LNPU10033 (syst. Spec.)mmol/LNPU18412 (fPt)mmol/LP- Kolesterol HDLNPU01567mmol/LNPU10157 (fPt)mmol/LNPU1807 (syst(spec.))mmol/LP- Kolesterol LDLNPU01668mmol/LNPU10171 (fPt)mmol/LDNK35308 (beregnet)mmol/LP- KreatininNPU18016umol/LNPU04998 (enzymatisk)umol/LNPU01807 (beregnet ved Jaffe-metode)umol/LNPU09101 (Jaffe)mmol/LP- NatriumNPU03429mmol/Lp-TSHNPU0357710-3 IU/LNPU2754710-3 IU/Lp-triglyceridNPU04094mmol/LNPU03620 (fPt)mmol/LNPU18106 (syst(spec))mmol/Lp-uratNPU09356umol/LNPU03688mmol/Lp-ureaNPU01459mmol/L\n\nvar dest = document.getElementById(\"2edba282-ec9c-4165-8d35-b3d1c3c3392f\");\nvar template = document.getElementById(\"12ff4a57-56e4-4195-a4b7-416d8c16ca26\");\nvar caption = template.content.querySelector(\"caption\");\nif(caption) {\n  caption.style.cssText = \"display:block;text-align:center;\";\n  var newcapt = document.createElement(\"p\");\n  newcapt.appendChild(caption)\n  dest.parentNode.insertBefore(newcapt, dest.previousSibling);\n}\nvar fantome = dest.attachShadow({mode: 'open'});\nvar templateContent = template.content;\nfantome.appendChild(templateContent);\n\nList of requested ICD-8 and -10 codes\nDa hovedformålet med projektet er at undersøge prævalensen og incidensen af diabetes, relaterede kardiometaboliske sygdomme samt følgesygdomme (komplikationer) i sociale netværk ønsker vi nedenstående ICD10 samt ICD8 koder. Efter koderne har vi kort redegjort for, hvorfor vi ansøger om netop de listede koder.\n\n\n.tabwid table{\n  border-collapse:collapse;\n  line-height:1;\n  margin-left:auto;\n  margin-right:auto;\n  border-width: 0;\n  display: table;\n  margin-top: 1.275em;\n  margin-bottom: 1.275em;\n  border-spacing: 0;\n  border-color: transparent;\n}\n.tabwid_left table{\n  margin-left:0;\n}\n.tabwid_right table{\n  margin-right:0;\n}\n.tabwid td {\n    padding: 0;\n}\n.tabwid a {\n  text-decoration: none;\n}\n.tabwid thead {\n    background-color: transparent;\n}\n.tabwid tfoot {\n    background-color: transparent;\n}\n.tabwid table tr {\nbackground-color: transparent;\n}\n.cl-30645360{border-collapse:collapse;}.cl-305cebca{font-family:'Times New Roman';font-size:12pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(255, 255, 255, 1.00);background-color:transparent;}.cl-305cebfc{font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-305cffa2{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-305d0006{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-305d48d6{width:126pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-305d4908{width:180pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-305d4912{width:108pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-305d4926{width:126pt;background-color:rgba(79, 129, 189, 1.00);vertical-align: top;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-305d493a{width:180pt;background-color:rgba(79, 129, 189, 1.00);vertical-align: top;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-305d4944{width:108pt;background-color:rgba(79, 129, 189, 1.00);vertical-align: top;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}\nTable 1: Diagnosis of diabetes and its forms and subtypes.\n\nSygdomsgruppeSygdommeICD10ICD8DiabetesType 1 diabetes mellitus; Type 2 mellitus; Andre diabetes subtyper; Diabetes med komplikationerE10-E14249-250\n\nvar dest = document.getElementById(\"97fe3221-432d-41bb-b2e3-f89132c530bb\");\nvar template = document.getElementById(\"668ed482-fee2-42af-afdd-1e57e27d23f9\");\nvar caption = template.content.querySelector(\"caption\");\nif(caption) {\n  caption.style.cssText = \"display:block;text-align:center;\";\n  var newcapt = document.createElement(\"p\");\n  newcapt.appendChild(caption)\n  dest.parentNode.insertBefore(newcapt, dest.previousSibling);\n}\nvar fantome = dest.attachShadow({mode: 'open'});\nvar templateContent = template.content;\nfantome.appendChild(templateContent);\n\n.tabwid table{\n  border-collapse:collapse;\n  line-height:1;\n  margin-left:auto;\n  margin-right:auto;\n  border-width: 0;\n  display: table;\n  margin-top: 1.275em;\n  margin-bottom: 1.275em;\n  border-spacing: 0;\n  border-color: transparent;\n}\n.tabwid_left table{\n  margin-left:0;\n}\n.tabwid_right table{\n  margin-right:0;\n}\n.tabwid td {\n    padding: 0;\n}\n.tabwid a {\n  text-decoration: none;\n}\n.tabwid thead {\n    background-color: transparent;\n}\n.tabwid tfoot {\n    background-color: transparent;\n}\n.tabwid table tr {\nbackground-color: transparent;\n}\n.cl-3080acfe{border-collapse:collapse;}.cl-3075eec2{font-family:'Times New Roman';font-size:12pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(255, 255, 255, 1.00);background-color:transparent;}.cl-3075eef4{font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-307603f8{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-30760416{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-30765772{width:108pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-3076579a{width:126pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-307657ae{width:180pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-307657c2{width:126pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-307657cc{width:180pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-307657e0{width:108pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-307657ea{width:126pt;background-color:rgba(79, 129, 189, 1.00);vertical-align: top;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-307657fe{width:180pt;background-color:rgba(79, 129, 189, 1.00);vertical-align: top;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-30765808{width:108pt;background-color:rgba(79, 129, 189, 1.00);vertical-align: top;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}\nTable 1: Diseases that contribute to, are associated with, or are complications or comorbidities of diabetes.\n\nSygdomsgruppeSygdommeICD10ICD8HjertekarsygdommeIskæmisk hjertesygdom; Hypertension; Arteriosklerose; Akut myokadieinfarkt; Hjerteinsufficiens; Karsygdomme; Cerebrovasculære sygdomme; TachycardiaI10-I13; I15; I20-I21; I23-I25; I44-I49; I50; I78-I79; R000400-404; 410-414; 426-429; 782.2;ØjensygdommeBetændelse i øjets bindehinde; Konjunktivitis; Andre sygdomme i øjets bindehinde; Sygdomme i sclera, kreatitis, cornea, hornhinde, iris; Grå stær; Katarakt; Forandringer i linse; Glaucoma; Grøn stærH10-H11; H15-H22; H25-H28; H30-H35; H36; H40; H42360-369; 370-372; 374-378Neurologiske og Neuro-degenererende sygdommeParkinson, Alzheimers, Iskæmi ved cerebrovaskulære sygdomme; Idiopatiske neuropatier; Polyneuropatier; Andre sygdomme i det perifere nervesystem; Sygdomme i autonome nervesystemG20-G22; G30; G45-G47; G60-G64; G90342; 348; 358Mentale sygdommeManisk enkeltepisode; Bipolær affektiv sindslidelse; Depression. Vedvarende affektive tilstande; SpiseforstyrrelseF30-F34; F38-F39; F50-F51296; 300.4; 301.1; 780.6; 780.7; 790.2Sygdomme i tænder og mundhuleKaries; Tandsygdomme; Sygdomme i mund, læber etc.K02-K05; K08; K12-K13521-523; 528FrakturerOsteoporose m/u frakturer; Patologiske frakturer; Knoglelidelser ved neoplastisk sygdommme klassificeret andetsteds; Knoglefrakturer og følgetilstand efter fraktur i bevægeapparatetM80-M81; M84; M84.4; M90.7; M96.6; S02; S12; S22; S32; S42; S52; S62; S72; S82; S92; T02; T08; T10; T12; T14.2; T90.2; T91.1; T91.2; T92.1; T92.2; T93.1; T93.2N800-N809; N810-N819; N820-N829HudsygdommeHordeolum og chalazion; Betændelse i øjenlåg; bylder; eksem; kløe; Psoriasis; DermatitisH00-H01; L02; L20-L21; L29-L30; L40; L60; L62; L72-L74; L83; L85.3; L92.0; L92.1; B37680; 690-692; 696; 698; 702-705Cystisk fibroseE84273Metaboliske sygdommeForstyrrelser i omsætningen makro- og mikronæringsstoffer; forskellige former af porfyri;E70-E80; E83; E85-E89270-272; 274-277PankreatitisPankratitis og andre sygdomme i bugspytkirtlenK85-K87577-579Thyreoidea SygdommeMedfødt jodmangelsyndrom; Jodmangel-relaterede lidelser i skjoldbruskkirtlen; Kompenseret jodmangelbetinget myksødem; Anden hypotyroidisme; Anden atoksisk struma; Tyrotoksikose Betændelse i skjoldbruskkirtlen; Andre sygdomme i skjoldbruskkirtlenE00-E07240-246Endokrine sygdommeParatyroidisme; Andre sygdomme i biskjoldbruskkirtel; Sygdomme i hypofysen; Hyperaldosteronisme; Andre binyresygdomme; Funktionsforstyrrelser i flere endokrine kirtler; Sygdomme i andre endokrine kirtlerE20-E32; E34-E35251-258AdipositasOvervægt; Fedme; Svær fedme; Ekstrem Fedme; OverernæringE65-E68277Mave-tarmsygdomme; Leversygdomme; Galdeblære- og bugspytkirtel-sygdomme; Fordøjelsessyg-dommeBetændelse i spiserøret; Gastro-øsofageal refluks; Andre sygdomme i spiserør; Ulcers; Karsygdomme i tarm; Tyktarmssygdomme; Andre forstyrrelser i tarmen; Leversygdomme; Galdeblæresygdomme; Nedsat optagelse af næringsstoffer fra tarmen; Andre sygdomme i fordøjelsessystemetK20-K23; K29-K31; K35-K38; K50-K52; K55-K59; K70-K77; K80-K83; K90-K93530; 535-537; 540-543; 561-564; 570-571; 573-576AnæmierAnæmier; Jernmangelanæmi; Anæmi, B12 mangel; Anæmi; Folinsyremangel; Ernæringsbetinget anæmi; Selgcellesygdomme; Hæmolytiske anæmierD50-D53; D55-D59; D60-D64280-289InfertilitertMandlig infertilitet; Kvindelig infertilitetN46; N97\n\nvar dest = document.getElementById(\"1dd59eb8-d125-4bcd-810c-652b9423d951\");\nvar template = document.getElementById(\"ea979c18-0be9-4376-96e1-21a90a9f2772\");\nvar caption = template.content.querySelector(\"caption\");\nif(caption) {\n  caption.style.cssText = \"display:block;text-align:center;\";\n  var newcapt = document.createElement(\"p\");\n  newcapt.appendChild(caption)\n  dest.parentNode.insertBefore(newcapt, dest.previousSibling);\n}\nvar fantome = dest.attachShadow({mode: 'open'});\nvar templateContent = template.content;\nfantome.appendChild(templateContent);\n\n.tabwid table{\n  border-collapse:collapse;\n  line-height:1;\n  margin-left:auto;\n  margin-right:auto;\n  border-width: 0;\n  display: table;\n  margin-top: 1.275em;\n  margin-bottom: 1.275em;\n  border-spacing: 0;\n  border-color: transparent;\n}\n.tabwid_left table{\n  margin-left:0;\n}\n.tabwid_right table{\n  margin-right:0;\n}\n.tabwid td {\n    padding: 0;\n}\n.tabwid a {\n  text-decoration: none;\n}\n.tabwid thead {\n    background-color: transparent;\n}\n.tabwid tfoot {\n    background-color: transparent;\n}\n.tabwid table tr {\nbackground-color: transparent;\n}\n.cl-30971976{border-collapse:collapse;}.cl-308f53bc{font-family:'Times New Roman';font-size:12pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(255, 255, 255, 1.00);background-color:transparent;}.cl-308f53ee{font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-308f6bfe{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-308f6c30{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-308fbbe0{width:162pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-308fbc12{width:162pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-308fbc1c{width:162pt;background-color:rgba(79, 129, 189, 1.00);vertical-align: top;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}\nTable 1: Diseases that are components of the ‘Charleson’s Morbidity Index’.\n\nSygdommeICD10ICD8Akut myokardieinfarktI21; I23410HjerteinsufficiensI50; I11; I13427-428; 782KarsygdommeI70-I74; I77440-445DemensF00-F03; F05; G30290; 293Cerebrovaskulære sygdommeI60-I69; G45-G46430-438Kroniske lungesygdommeJ40-J47; J60-J67; J684; J70; J841; J920; J961; J982; J983490-493; 515-518BindevævssygdommeM05-M06; M08-M09; M30-M36; D86135; 712; 716; 734; 446UlcussygdommeK221; K25-K28530; 531-534Milde leversygdommeB18; K700; K71; K73-K74; K760571; 573HemiplegiG81-G82344NyresygdommeI12-I13; N00-N05; N07; N11; N14; N17-N19; Q61403-404; 580-584; 590; 593; 753; 792Solide kræftformerC00-C75140-194LeukæmiC91-C95204-207LymfomerC81-C85; C88; C90; C96200-203; 275Moderate til svære leversygdommeB15-B16; B19; K70; K72; K76; I85070; 456; 573Metastaserende cancerC76-C80195-199AIDSB21-B2479\n\nvar dest = document.getElementById(\"0fe52de3-10b4-4229-bba9-60e152af86c0\");\nvar template = document.getElementById(\"171a77fc-f7b6-406a-8db3-c2f87db5dfc1\");\nvar caption = template.content.querySelector(\"caption\");\nif(caption) {\n  caption.style.cssText = \"display:block;text-align:center;\";\n  var newcapt = document.createElement(\"p\");\n  newcapt.appendChild(caption)\n  dest.parentNode.insertBefore(newcapt, dest.previousSibling);\n}\nvar fantome = dest.attachShadow({mode: 'open'});\nvar templateContent = template.content;\nfantome.appendChild(templateContent);\n\nJustification for requested disease codes\nThe overall aim of this project is to identify the contributions of family and early life determinants on the development, management and care of diabetes and the diseases that may arise following a diabetes diagnosis, under a life-course framework. The justification for requesting data on multiple disease areas directly follows the primary aim of this project. We investigate this aim focusing on diabetes as the central disease of interest. Diabetes consists of different subtypes (Type 1, Type 2, LADA, MODY, gestational diabetes, secondary diabetes, rare monogenic forms) each with a different set of risk factors, presentation and pathophysiological characteristics. The familial and social effects that are the subject of this project are likely to be different for each of these diabetes subtypes. E.g. for some types of diabetes, caused predominantly by auto-immune mechanisms, familial associations to other auto-immune diseases are more likely than for type 2 diabetes, which is driven to a strong degree by obesity, low physical activity and insulin resistance.\nAll forms of diabetes have an increased blood glucose level as their central hallmark, and are associated with major and minor complications. The vascular complications are generally subdivided into large-vessel disease (macrovascular): myocardial infarction, stroke, peripheral vascular disease; and small-vessel disease (diabetic retinopathy, neuropathy nephropathy). The occurrence of these complications is not dependent solely on the elevated glucose levels, but also on disturbance of other metabolic risk factors, familial predisposition and pre-existing conditions. Beyond these classical complications, increasingly links between diabetes and other complications are being recognised: depression, cancer, loss of cognitive function, skin conditions.\nAn important feature of diabetes is that it can be undetected for several years, and that the diabetic complications can sometimes be the first presentation of the disease. In order to study the occurrence of diabetic complications in the context of family we need to assess the complication status for all traditional and novel diabetic complication.\nAdequate treatment of diabetes depends on long-term engagement and motivation of the patient for self-management of different aspects of the disease. The capacity to respond adequately to this challenge depends to a large degree on socio-economic status, including the degree of social support in the direct environment surrounding the patient. These effects occur in interaction with other chronic conditions, including mental health conditions.\nThe justification for the requested list of conditions falls into four categories:\nDiagnosis of diabetes itself, in all its forms and subtypes.\nConditions that are an established cause of diabetes, and diseases which have an emerging association with diabetes, which we wish to investigate\nMajor and minor complications and other consequences / signs of diabetes\nConditions needed to adjust our analyses for the simultaneous occurrence of other chronic health problems (co-morbidity)\nDescription of disease and its relation to diabetes\nCardiovascular disease is the most common cause of death and disability among people with diabetes The cardiovascular diseases that accompany diabetes include angina, myocardial infarction (heart attack), stroke, peripheral artery disease and congestive heart failure. High blood pressure, high cholesterol, high blood glucose and other risk factors contribute to the increased risk of cardiovascular complications.\nEye diseases: Diabetic retinopathy and macular edema are the major eye complications of diabetes; but diabetic eye disease also includes cataract and glaucoma. Furthermore, infections of the eyelid and adnexa are also seen.\nNeurological and neurodegenerative diseases: Diabetic peripheral and autonomic neuropathy are part of the major diabetic microvascular complications. Furthermore, diabetes has long been linked to vascular dementia; probably mediated through chronic ischaemia, endothelial dysfunction and micro-strokes. In the past decade, increasing evidence has emerged for a shared pathophysiological and aetiological connection between diabetes and Parkinson’s disease, Alzheimer’s disease, dementia, loss of cognitive function.\nMental health conditions have been linked to diabetes in different ways. The most established link is between depression and diabetes, both as a cause and a consequence, but also an association with schizophrenia has been observed and is receiving increasing attention. Mental health can deteriorate as a consequence of living with diabetes, and poor mental health, including personality and eating disorders can impair a patient’s ability to cope adequately with the demands (changes in lifestyle, self-measurement and management, self-care) posed by the presence of long-standing diabetes. Consequently, patients with co-morbid diabetes and mental health problems tend to have worse control and outcomes for both conditions. Moreover, mental health conditions also affect people’s abilities to build up and maintain social connections, and they may place strain on family relations, potentially altering their influence on health compared to the general population.\nOrodental health: There is a well-established link between diabetes and orodental health. Diabetes is a risk factor for periodontal diseases such as gingivitis and periodontitis, and the relation is though to be bidirectional, meaning that not only does diabetes increase the occurrence of orodental problems, but also that orodental conditions may affect the metabolic control of diabetes in diabetic patients.\nFractures are associated with diabetes both directly and indirectly (as a consequence of loss of eyesight or loss of sensation in the feet due to diabetic retinopathy and neuropathy). Moreover, fractures, especially in the elderly are a strong cause of co-morbidity and can exacerbate other chronic health problems.\nGastro-intestinal diseases:\nDiabetes is ultimately a disease of imbalance in the carbohydrate metabolism, and is closely linked to lipid metabolism. Besides the liver, there is an increasing insight that the gut plays an important regulatory role. Several mechanisms linked to appetite and satiety have been found to be regulated in feed-back loops involving the gut (particularly the duodenum). This is expressed in the marked improvement in metabolic control seen in patients with diabetes who undergo Roux-en-Y gastric bypass operations and the impact on obesity of a Glucagon-like peptide-1 analogues.\nAnother emerging line of research linking the health of the gut to diabetes is the study of the intestinal microbiome. This emerging field is showing increasingly convincing associations between diet, the composition of the bacterial populations in the gut and obesity, CVD and several metabolic diseases including diabetes. It follows that any condition that causes gut inflammation, and malabsorption, such as Irritable Bower Syndrome, Crohn’s disease or gastric and duodenal ulcers, may affect the intestinal microflora, and through that mechanism diabetes risk.\nExisting diabetes can also cause gut symptoms; patients with severely disregulated diabetes sometimes present with gastroparesis and constipation, which can be seen as a consequence of failed autonomic regulation of gut motility due to diabetic autonomic neuropathy.\n\nLiver diseases: Insulin resistance, a central determinant of type 2 diabetes, is principally determined by insulin resistance in the muscles (peripheral) and in the liver (central). Diseases that affect liver function, through inflammation, fat accumulation, fibrosis or a combination of these mechanisms, have an impact of central insulin resistance. This phenomenon is recognised in the strong relationship between Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) with diabetes and the metabolic syndrome. The central role of the liver, and liver conditions, to diabetes, also provides a conceptual link to other metabolic conditions in which the liver plays a central role, such as iron and lipid metabolism.\nKidney diseases: Diabetic kidney disease is one of the main microvascular complications of diabetes, progressing from a mild initial presentation (micro-albuminuria) to advanced (macro-albuminuria) and late stages (end-stage renal disease, ultimately with renal failure and the need for dialysis). Loss of renal function itself (both in the presence and absence of diabetes) is recognised as a risk factor for the development of cardiovascular disease. Diabetic kidney disease thus also provides a direct pathophysiological link to the management of hypertension in people with diabetes.\nAnaemia and Iron metabolism: Iron metabolism has long been implicated as a causal factor in cardiovascular disease aetiology, but there is mounting evidence pointing to a causal link the occurrence of diabetes. Low iron stores and iron deficiency anaemia can have an impact on the ability to use HbA1c as a valid indicator of average glucose levels over a longer period of time. Anaemia is also a strong indicator of general ill health and should be considered when studying diabetes in a context of multi-morbidity.\nSkin diseases: Several dermatological conditions, including psoriasis, dermatitis and eczema, are seen more frequently in patients with diabetes. Peripheral neuropathy affects the skin’s ability to activate sweat glands, leading to dry and brittle skin and higher occurrence of skin infections, which exacerbate diabetic foot problems.\nInfertility: Fertility problems are well known for women with diabetes and male infertility is a likely but less studied consequence of diabetes.\nList of requested ATC codes\n\n\n.tabwid table{\n  border-collapse:collapse;\n  line-height:1;\n  margin-left:auto;\n  margin-right:auto;\n  border-width: 0;\n  display: table;\n  margin-top: 1.275em;\n  margin-bottom: 1.275em;\n  border-spacing: 0;\n  border-color: transparent;\n}\n.tabwid_left table{\n  margin-left:0;\n}\n.tabwid_right table{\n  margin-right:0;\n}\n.tabwid td {\n    padding: 0;\n}\n.tabwid a {\n  text-decoration: none;\n}\n.tabwid thead {\n    background-color: transparent;\n}\n.tabwid tfoot {\n    background-color: transparent;\n}\n.tabwid table tr {\nbackground-color: transparent;\n}\n.cl-30cecefc{border-collapse:collapse;}.cl-30bdf4e2{font-family:'Times New Roman';font-size:12pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(255, 255, 255, 1.00);background-color:transparent;}.cl-30bdf53c{font-family:'Times New Roman';font-size:12pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-30bdf546{font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-30be0c98{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-30be0cc0{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-30bf5076{width:144pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-30bf50da{width:360pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-30bf50ee{width:144pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-30bf5102{width:360pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-30bf510c{width:144pt;background-color:rgba(79, 129, 189, 1.00);vertical-align: top;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-30bf5120{width:360pt;background-color:rgba(79, 129, 189, 1.00);vertical-align: top;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}\nTable 2: Requested ATC codes in classifying diabetes and cardiovascular diseases.\n\nATC CodeDescriptionAAlimentary tract and metabolismaA08Antiobesity preparations, excluding diet productsA08AAnti obesity drugs list, excluding diet productsA08AACentrally acting anti obesity drugsA08ABPeripherally acting anti obesity drugsA08AXOther anti obesity drugsA10Drugs used in diabetesA10AInsulins and analoguesA10ABInsulins and analogues for injection, fast-actingA10AB01Insulin (human)A10AB02Insulin (beef)A10AB03Insulin (pork)A10AB04Insulin lisproA10AB05Insulin aspartA10AB06Insulin glulisineA10AB30CombinationsA10ACInsulins and analogues for injection, intermediate-actingA10AC01Insulin (human)A10AC02Insulin (beef)A10AC03Insulin (pork)A10AC04Insulin lisproA10AC30CombinationsA10ADInsulins and analogues for injection, intermediate- or long-acting combined with fast-actingA10AD01Insulin (human)A10AD02Insulin (beef)A10AD03Insulin (pork)A10AD04Insulin lisproA10AD05Insulin aspartA10AD06Insulin degludec and insulin aspartA10AD30CombinationsA10AEInsulins and analogues for injection, long-actingA10AE01Insulin (human)A10AE02Insulin (beef)A10AE03Insulin (pork)A10AE04Insulin glargineA10AE05Insulin detemirA10AE06Insulin degludecA10AE30CombinationsA10AE54Insuline glargine and lixisenatideA10AE56Insulin degludec and liraglutideA10AFInsulins and analogues for inhalationA10AF01Insulin (human)A10BBlood glucose lowering drugs, excluding insulinsA10BABiguanidesA10BA01PhenforminA10BA02MetforminA10BA03BuforminA10BBSulfonylureasA10BB01GlibenclamideA10BB02ChlorpropamideA10BB03TolbutamideA10BB04GlibornurideA10BB05TolazamideA10BB06CarbutamideA10BB07GlipizideA10BB08GliquidoneA10BB09GliclazideA10BB10MetahexamideA10BB11GlisoxepideA10BB12GlimepirideA10BB31AcetohexamideA10BCSulfonamides (heterocyclic)A10BC01GlymidineA10BDCombinations of oral blood glucose lowering drugsA10BD01Phenformin and sulfonylureasA10BD02Metformin and sulfonylureasA10BD03Metformin and rosiglitazoneA10BD04Glimepiride and rosiglitazoneA10BD05Metformin and pioglitazoneA10BD06Glimepiride and pioglitazoneA10BD07Metformin and sitagliptinA10BD08Metformin and vildagliptinA10BD09Pioglitazone and alogliptinA10BD10Metformin and saxagliptinA10BD11Metformin and linagliptinA10BD12Pioglitazone and sitagliptinA10BD13Metformin and alogliptinA10BD14Metformin and repaglinideA10BD15Metformin and dapagliflozinA10BD16Metformin and canagliflozinA10BD17Metformin and acarboseA10BD18Metformin and gemigliptinA10BD19Linagliptin and empagliflozinA10BD20Metformin and empagliflozinA10BD21Saxagliptin and dapagliflozinA10BD22Metformin and evogliptinA10BD23Metformin and ertugliflozinA10BD24Sitagliptin and ertugliflozinA10BD25Metformin, saxagliptin and dapagliflozinA10BD26Metformin and lobeglitazoneA10BFAlpha glucosidase inhibitorsA10BF01AcarboseA10BF02MiglitolA10BF03VogliboseA10BGThiazolidinedionesA10BG01TroglitazoneA10BG02RosiglitazoneA10BG03PioglitazoneA10BG04LobeglitazoneA10BHDipeptidyl peptidase 4 (DPP-4) inhibitorsA10BH01SitagliptinA10BH02VildagliptinA10BH03SaxagliptinA10BH04AlogliptinA10BH05LinagliptinA10BH06GemigliptinA10BH07EvogliptinA10BH08TeneligliptinA10BH51Sitagliptin and simvastatinA10BH52Gemigliptin and rosuvastatinA10BJGlucagon-like peptide-1 (GLP-1) analoguesA10BJ01ExenatideA10BJ02LiraglutideA10BJ03LixisenatideA10BJ04AlbiglutideA10BJ05DulaglutideA10BJ06SemaglutideA10BJ07BeinaglutideA10BKSodium-glucose co-transporter 2 (SGLT2) inhibitorsA10BK01DapaglifozinA10BK02CanagliflozinA10BK03EmpagliflozinA10BK04ErtugliflozinA10BK05IpragliflozinA10BK06SotagliflozinA10BK07LuseogliflozinA10BXOther blood glucose lowering drugs, excluding insulinsA10BX01Guar gumA10BX02RepaglinideA10BX03NateglinideA10BX05PramlintideA10BX06BenfluorexA10BX08MitiglinideA10BX10LixinatideA10XOther drugs used in diabetesA10XAAldose reductase inhibitorsA10XA01TolrestatBBlood and blood forming organsB01AAntithrombotic agentsB01AB01AAB01AA03WarfarinB01ACPlatelet aggregation inhibitors excluding heparinB01AC04ClopidogrelB01AC05TiclopidineB01AC06Acetylsalicylic acidB01AC07DipyridamoleB01AC16EptifibatideB01AC24TicagrelorB01AC25CangrelorB01AEDirect thrombin inhibitorsB01AE07Dabigatran etexilateB01AFDirect factor Xa inhibitorsB01AF01RivaroxabanB01AF02ApixabanB01AF03EdoxabanB03Antianemic drugsB03AIron preparationsB03ABIron trivalent, oral preparationsB03ADIron in combination with folic acidB03AEIron in other combinationsB03BVitamin B12 and folic acidB03BAVitamin B12 (cyanocobalamin and analogues)B03BBFolic acid and derivativesB03XOther antianemic preparationsB03XAB03XA01ErythropoietinB03XA02Darbepoetin alfaB03XA03Methoxy polyethylene glycol-epoetin betaB03XA04PeginesatideCCardiovascular systemC01Cardiac therapyC01ACardiac glycosides listC01AADigitalis glycosidesC01AA04DigitoxinC01AA05DigoxinC01BClass 1 and 3 antiarrhythmic drugsC01BAClass 1a antiarrhythmic drugsC01BBClass 1b antiarrhythmic drugsC01BCClass 1c antiarrhythmic drugsC01BC04FlecainideC01BDClass 3 antiarrhythmic drugsC01BD01AmiodaroneC01BGClass 1 and 3 antiarrhythmic drugsC03Diuretic drugsC03ALow-ceiling diuretics, thiazidesC03AAThiazides, plainC03ABThiazides and potassium in combinationC03AHThiazides, combinations with psycholeptics and/or analgesicsC03AXThiazides, combinations with other drugsC03CHigh-ceiling diureticsC03CASulfonamides, plainC03CBSulfonamides and potassium in combinationC03CCAryloxyacetic acid derivativesC03CDPyrazolone derivativesC03CXOther high-ceiling diureticsC03DPotassium-sparing agentsC03DAAldosterone antagonistsC03DA01SpironolactoneC03DA02Potassium canrenoateC03DA03CanrenoneC03DA04EplerenoneC07Beta blocking agentsC07ABeta blocking agentsC07AABeta blocking agents, non-selectiveC07ABBeta blocking agents, selectiveC07AGAlpha and beta blocking agentsC07BBeta blocking agents and thiazidesC07BABeta blocking agents, non-selective, and thiazidesC07BBBeta blocking agents, selective, and thiazidesC07BGAlpha and beta blocking agents and thiazidesC07CC07CABeta blocking agents, non-selective, and other diureticsC07CBBeta blocking agents, selective, and other diureticsC07CGAlpha and beta blocking agents and other diureticsC07DC07DABeta blocking agents, non-selective, thiazides and other diureticsC07DBBeta blocking agents, selective, thiazides and other diureticsC07FC07FABeta blocking agents, non-selective, and other antihypertensivesC07FBBeta blocking agents, selective, and other antihypertensivesC07FXBeta blocking agents, other combinationsC08Calcium channel blockersC08CSelective calcium channel blockers with mainly vascular effectsC08CADihydropyridine derivativesC08CXOther selective calcium channel blockers with mainly vascular effectsC08DSelective calcium channel blockers with direct cardiac effectsC08DAPhenylalkylamine derivativesC08DBBenzothiazepine derivativesC09Agents acting on the renin-angiotensin systemC09AACE inhibitors, plainC09AAACE inhibitors, plainC09AA01CaptoprilC09AA02EnalaprilC09AA03LisinoprilC09AA04PerindoprilC09AA05RamiprilC09AA06QuinaprilC09AA07BenazeprilC09AA08CilazaprilC09AA09FosinoprilC09AA10TrandolaprilC09AA11SpiraprilC09AA12DelaprilC09AA13MoexiprilC09AA14TemocaprilC09AA15ZofenoprilC09AA16ImidaprilC09CAngiotensin II receptor blockers (ARBs)plainC09CAAngiotensin II receptor blockers (ARBs)plainC09CA01LosartanC09CA02EprosartanC09CA03ValsartanC09CA04IrbesartanC09CA05TasosartanC09CA06CandesartanC09CA07TelmisartanC09CA08Olmesartan medoxomilC09CA09Azilsartan medoxomilC09CA10FimasartanC09DAngiotensin II receptor blockers (ARBs), combinationsC09DXC09DX04Valsartan and sacubitrilC10Lipid modifying agentsC10ALipid modifying agents, plainC10AAHMG CoA reductase inhibitorsC10AA01SimvastatinC10AA02LovastatinC10AA03PravastatinC10AA04FluvastatinC10AA05AtorvastatinC10AA06CerivastatinC10AA07RosuvastatinC10AA08PitavastatinGGenitourinary system and reproductive hormonesG04Urological drugsG04BUrologicalsG04BEDrugs used in erectile dysfunctionG04BE01AlprostadilG04BE02PapaverineG04BE03SildenafilG04BE04YohimbinG04BE06MoxisylyteG04BE07ApomorphineG04BE08TadalafilG04BE09VardenafilG04BE10AvanafilG04BE11UdenafilG04BE30CombinationsG04BE52Papaverine, combinationsHSystemic hormonal preparations, excluding reproductive hormones and insulinsH02Corticosteroids systemicH02ACorticosteroids for systemic use, plainH02AAMineralocorticoidsH02ABGlucocorticoidsH02BH02BXCorticosteroids for systemic use, combinationsH02BX01Methylprednisolone, combinationsH03Thyroid therapyH03AThyroid preparationsH03AAThyroid hormonesH03BAntithyroid preparationsH03BAThiouracilsH03BBSulphur-containing imidazole derivativesH03BCPerchloratesH03BXOther antithyroid preparationsNNervous systemN06PsychoanalepticsN06AAntidepressant drugsN06AANon-selective monoamine reuptake inhibitorsN06ABSelective Serotonin Reuptake InhibitorsN06AFMonoamine oxidase inhibitors, non-selectiveN06AGMonoamine oxidase A inhibitorsN06AXOther antidepressant drugs\n\nvar dest = document.getElementById(\"fe052bac-abff-4a0d-8df9-a2260a8aea66\");\nvar template = document.getElementById(\"da3929b0-5cbf-479f-ab97-0131c45b4c99\");\nvar caption = template.content.querySelector(\"caption\");\nif(caption) {\n  caption.style.cssText = \"display:block;text-align:center;\";\n  var newcapt = document.createElement(\"p\");\n  newcapt.appendChild(caption)\n  dest.parentNode.insertBefore(newcapt, dest.previousSibling);\n}\nvar fantome = dest.attachShadow({mode: 'open'});\nvar templateContent = template.content;\nfantome.appendChild(templateContent);\n\n\n\n\n",
      "last_modified": "2021-09-03T16:21:13+02:00"
    },
    {
      "path": "description.html",
      "title": "Project description for DST application",
      "author": [
        {
          "name": "Luke W. Johnston",
          "url": "https://lukewjohnston.com/"
        }
      ],
      "contents": "\n\nContents\nAutoriseret institution / Authorised institution\nProjekttitel / Project title\nProjektbeskrivelse / Project description\nPopulation / Population\nVariabelindhold / Variables included\nSærligt vedr. lægemiddelsdata / Especially regarding drug data\nOffentliggørelse af resultater / Publication of results\nPerspektivering / Perspective\nData som ikke kommer fra Danmarks Statistik / Data that doesn’t come from DST\nProjekts slutdato / Project’s end date\nAutoriserede forskere / Authorised scientists\nUnderskrift / Signatures\n\nForskningsservice Dato September 03, 2021 Projekt nr. 70xxxx/ kontaktperson i Forskningsservice\nAutoriseret institution / Authorised institution\nEnhedschef Annelli Sandbæk\nSteno Diabetes Center Aarhus (inst. nr. 574)\nHedeager 3, 2. sal\n8200 Aarhus\nDenmark\nProjekttitel / Project title\nInterplay between diabetes and intergenerational transmission of health determinants over the life course\nProjektbeskrivelse / Project description\nThe overall aim of this project is to identify the contributions of family and early life determinants on the development, management, and care of diabetes and the diseases that may arise following a diabetes diagnosis, under a life-course framework.\nDiabetes is a complex, multi-factorial disease. Its development depends on the timing and accumulation of exposures throughout the life-course. In addition to genetic influences, behavioral risk factors and socioeconomic conditions cluster in families and are passed through generations. For instance, poor childhood socioeconomic status (SES) can impact final educational attainment, adult SES, and lifestyle and behavioral characteristics, which ultimately influence an individual’s metabolic capacity to regulate glucose and subsequent risk for diabetes.\nThis project will contribute to a broader and deeper understanding of the role that these factors play with the development and progression of diabetes. For this purpose, we will apply causal and predictive statistical methods to best use the data available from the integrated data sources with an overarching goal to model several potential public health strategies that might impact the prevention and management of diabetes and the diseases that follow its diagnosis.\n\n\nPopulation / Population\nIn order to identify familial relations through individuals’ life course trajectory, the population requested covers all individuals, who live or lived in Denmark from 1 January 1970 to 31 December 2020 (~8.5 million people). The family linkage and structure makes the construction of the population complicated and we will do this ourselves. For that we need the entire population because we need data on not just the individual, but also the family (parents and siblings). To characterise early life and early childhood conditions of an individual person, we need data on their parents. Likewise, to understand the role that the family network, including siblings and grandparents, has on diabetes risk, we need a large enough population to make these linkages and to adequately study this area. Key requirements are:\nAll index individuals born or who migrated into Denmark on or after 1970-01-01.\nAll family members of the index individuals, including parents, siblings, spouses, and children.\nVariabelindhold / Variables included\nAll variables can be de-identified (direct identification is not needed). The list of requested variables is found in the tables at the end of the document in the Appendix. For all the variables, we need the data from the first year it is available to the most recent year it is available.\nRegisters requested are:\n\nAKM: Arbejdsklassifikationsmodulet / The work classification module\nBEF: Befolkningen / The population\nCPST: CPR Status / Civil Registration Status\nDOD: Døde i Danmark / Died in Denmark\nDODSAARS: Dødsårssagsregistret / Cause of death register\nDODSAASG: Dødsårsagsregister / Cause of death register\nFAIK: Familieindkomster / Family income\nFAIN: Husstande og familier / Households and families\nFTBARN: Fertilitet - børn / Fertility - children\nFTDB: Fertilitetsdatabasen børn / Fertility database children\nFTDK: Fertilitetsdatabasen paritetsfil kvinder / Fertility database parity file women\nFTDM: Fertilitetsdatabasen paritetsfil mænd / Fertility database parity file men\nFTFORAEL: Fertilitet - forælder / Fertility - parent\nIDAN: IDA ansættelser / IDA employment\nIDAP: IDA persondata / IDA person data\nIEPE: Indvandrere og Efterkommere / Immigrants and Descendants\nIND: Indkomst / Income\nLMDB: Lægemiddeldatabasen / The drug database\nLPR_ADM: Landspatientregistret - administrative oplysninger / National Patient Register - administrative information\nLPR_BES: Landspatientregistret - ambulante besøgsdatoer / National Patient Register - outpatient visit dates\nLPR_DIAG: Landspatientregistret - diagnoser / National Patient Register - diagnoses\nLPR_OPR: Landspatientregistret - operationer efter ICD8 klassifikationen / National Patient Register - operations according to the ICD8 classification\nLPR_SKSOPR: Landspatientregistret - operationer / National Patient Register - operations\nLPR_SKSUBE: Landspatientregistret - undersøgelser og behandlinger / National Patient Register - examinations and treatments\nLPRMFRDF: Dødfødte ud fra LPR / Stillbirths from LPR\nLPRMFRLF: Levendefødte ud fra LPR / Live births from LPR\nSHSS: Sammenhængende socialstatistik / Coherent social statistics\nSSNV: Sammenhængende socialstatistik nettovarigheder / Coherent social statistics net durations\nSSSY: Sygesikring (6-cifret) / Health insurance (6-digit)\nSYSI: Sygesikring (sikringsgruppe) / Health insurance (group)\nUDDA: Uddannelser (BUE) / Education (BUE)\nVNDS: Historiske vandringer / Historical migration\n\nIn the Appendix we listed the ATC codes from the prescription register and ICD-8 and -10 codes from the patient register that we need to classify diabetes and the diseases that may arise following a diabetes diagnosis.\n\n\n\nSærligt vedr. lægemiddelsdata / Especially regarding drug data\nThe medication data we are requested are used in order to identify cases of disease (e.g. diabetes) that might not have been diagnosed and recorded in the patient register. The list of requested ATC codes is found in the Appendix section.\n\nOffentliggørelse af resultater / Publication of results\nResults will be published in open access scientific outlets and presented at scientific conferences.\nPerspektivering / Perspective\nUnderstanding how early life and familial factors can influence diabetes provides us with tools and knowledge to better target, intervene, and either prevent or manage diabetes and its complications. Considering the impact that diabetes as a disease itself and its related comorbidities has at the personal, public health, and economic level, any improvement in knowledge can have major impacts.\n\nData som ikke kommer fra Danmarks Statistik / Data that doesn’t come from DST\nData coming from other sources (e.g. Sundhedsdatastyrelsen):\n\n\nCancerregisteret: Cancerregisteret / Cancer Register\nDBDD: Dansk Børne Diabetes Database / Danish Childrens Diabetes Database\nDiabase: Diabase / Diabase\nDND: Det Nationale Diabetesregister / National Diabetes Register\nDVDD: Dansk Voskne Diabetes Database / Danish Adults Diabetes Database\nIVF: IVF-registeret / In vitro fertilization register\nLABKA: Clinical data / Clinical data\nLPR_PSYK: Landspatientregistret – psykologi / National Patient Register - psychological\n\nProjekts slutdato / Project’s end date\nDate of deletion of data: Access to data is requested until 2030-12-31.\n\nAutoriserede forskere / Authorised scientists\n\n\n.tabwid table{\n  border-collapse:collapse;\n  line-height:1;\n  margin-left:auto;\n  margin-right:auto;\n  border-width: 0;\n  display: table;\n  margin-top: 1.275em;\n  margin-bottom: 1.275em;\n  border-spacing: 0;\n  border-color: transparent;\n}\n.tabwid_left table{\n  margin-left:0;\n}\n.tabwid_right table{\n  margin-right:0;\n}\n.tabwid td {\n    padding: 0;\n}\n.tabwid a {\n  text-decoration: none;\n}\n.tabwid thead {\n    background-color: transparent;\n}\n.tabwid tfoot {\n    background-color: transparent;\n}\n.tabwid table tr {\nbackground-color: transparent;\n}\n.cl-3276e140{border-collapse:collapse;}.cl-326c9cee{font-family:'Bitstream Vera Sans';font-size:9pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-326c9d3e{font-family:'Bitstream Vera Sans';font-size:9pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-326cb6fc{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-326cb724{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-326eff20{width:54pt;background-color:rgba(242, 242, 242, 1.00);vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-326eff66{width:54pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-326eff7a{width:54pt;background-color:rgba(242, 242, 242, 1.00);vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-326eff8e{width:54pt;background-color:rgba(217, 217, 217, 1.00);vertical-align: top;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(102, 102, 102, 1.00);border-left: 1pt solid rgba(102, 102, 102, 1.00);border-right: 1pt solid rgba(102, 102, 102, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}NavnStillingsbetegnelseAnsættelsessted (Institution & Afdeling)IdentEmailMobilFysisk token ønskesHjemsendelse tilladesBrugeraftale på engelskKontaktpersonLuke W. JohnstonClinical researcherSteno Diabetes Center Aarhusluke.johnston@rm.dkNejNejJaØvrige personerOmar SilvermanClinical researcherSteno Diabetes Center Aarhusjossil@rm.dkNejNejJaDaniel R. WitteProfessorSteno Diabetes Center Aarhus and Institute for Public Health, Aarhus Universitydaniel.witte@ph.au.dkNejNejJaGunnar ToftSenior ResearcherSteno Diabetes Center Aarhusguntof@rm.dkNejNejNejAdam HulmanSenior Data ScientistSteno Diabetes Center Aarhusadahul@rm.dkNejJaJaAnnelli SandbækUnit ManagerSteno Diabetes Center Aarhusanesnd@rm.dkNejJaNej\n\nvar dest = document.getElementById(\"daddec34-fc3c-475a-bb15-2487fd256c15\");\nvar template = document.getElementById(\"2693d4df-8762-4643-b8fc-e6d55ca56f15\");\nvar caption = template.content.querySelector(\"caption\");\nif(caption) {\n  caption.style.cssText = \"display:block;text-align:center;\";\n  var newcapt = document.createElement(\"p\");\n  newcapt.appendChild(caption)\n  dest.parentNode.insertBefore(newcapt, dest.previousSibling);\n}\nvar fantome = dest.attachShadow({mode: 'open'});\nvar templateContent = template.content;\nfantome.appendChild(templateContent);\n\n\nUnderskrift / Signatures\nUnderskriver bekræfter på vegne af den dataansvarlige autoriserede institution, at den konkrete behandling er lovlig i henhold til databeskyttelsesforordningen artikel 6.\nUnderskriver bekræfter ligeledes at være formelt ansat på den dataansvarlige autoriserede institution, der indstiller projektet.\n\n\n\nPå vegne af den dataansvarlige:\n\n\n.tabwid table{\n  border-collapse:collapse;\n  line-height:1;\n  margin-left:auto;\n  margin-right:auto;\n  border-width: 0;\n  display: table;\n  margin-top: 1.275em;\n  margin-bottom: 1.275em;\n  border-spacing: 0;\n  border-color: transparent;\n}\n.tabwid_left table{\n  margin-left:0;\n}\n.tabwid_right table{\n  margin-right:0;\n}\n.tabwid td {\n    padding: 0;\n}\n.tabwid a {\n  text-decoration: none;\n}\n.tabwid thead {\n    background-color: transparent;\n}\n.tabwid tfoot {\n    background-color: transparent;\n}\n.tabwid table tr {\nbackground-color: transparent;\n}\n.cl-3289aad2{border-collapse:collapse;}.cl-3282f03e{font-family:'DejaVu Sans';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-32830330{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-328332f6{width:144pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-3283331e{width:324pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}Navn:Annelli SandbækStilling:EnhedschefDato:Underskrift:\n\nvar dest = document.getElementById(\"4bb2e209-22d0-4343-8447-3b9267928822\");\nvar template = document.getElementById(\"d17dfc2e-ecd5-4bba-bf1c-701bcccf3e57\");\nvar caption = template.content.querySelector(\"caption\");\nif(caption) {\n  caption.style.cssText = \"display:block;text-align:center;\";\n  var newcapt = document.createElement(\"p\");\n  newcapt.appendChild(caption)\n  dest.parentNode.insertBefore(newcapt, dest.previousSibling);\n}\nvar fantome = dest.attachShadow({mode: 'open'});\nvar templateContent = template.content;\nfantome.appendChild(templateContent);\n\nGodkendt til ekstern adgang\n\n\n.tabwid table{\n  border-collapse:collapse;\n  line-height:1;\n  margin-left:auto;\n  margin-right:auto;\n  border-width: 0;\n  display: table;\n  margin-top: 1.275em;\n  margin-bottom: 1.275em;\n  border-spacing: 0;\n  border-color: transparent;\n}\n.tabwid_left table{\n  margin-left:0;\n}\n.tabwid_right table{\n  margin-right:0;\n}\n.tabwid td {\n    padding: 0;\n}\n.tabwid a {\n  text-decoration: none;\n}\n.tabwid thead {\n    background-color: transparent;\n}\n.tabwid tfoot {\n    background-color: transparent;\n}\n.tabwid table tr {\nbackground-color: transparent;\n}\n.cl-329ce476{border-collapse:collapse;}.cl-32957cae{font-family:'DejaVu Sans';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-3295934c{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-3295cbfa{width:144pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-3295cc2c{width:324pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}Navn:Nikolaj Borg BurmeisterStilling:KontorchefDato:Underskrift:\n\nvar dest = document.getElementById(\"a2bd7895-5ee9-4f81-9b2b-da2d2ea4b635\");\nvar template = document.getElementById(\"a1f8c806-580c-402b-8ea8-c94710e60f27\");\nvar caption = template.content.querySelector(\"caption\");\nif(caption) {\n  caption.style.cssText = \"display:block;text-align:center;\";\n  var newcapt = document.createElement(\"p\");\n  newcapt.appendChild(caption)\n  dest.parentNode.insertBefore(newcapt, dest.previousSibling);\n}\nvar fantome = dest.attachShadow({mode: 'open'});\nvar templateContent = template.content;\nfantome.appendChild(templateContent);\n\n\n\n\n",
      "last_modified": "2021-09-03T16:21:16+02:00"
    },
    {
      "path": "index.html",
      "title": "*M*etabolic consequences of *E*arly *L*ife adversity and subsequent risk for type 2 *D*iabetes (MELD) Project",
      "description": "Application to request data from Denmark Statistics",
      "author": [
        {
          "name": "Luke W. Johnston",
          "url": "https://lukewjohnston.com/"
        }
      ],
      "date": "`r Sys.Date()`",
      "contents": "\nProject Description with justification and other necessary information for DST. See the word document sent to DST for how it should look like.\nProject Appendix with tables of requested registers and variables from DST. See the word document sent to DST for how it should look like.\n\n\n\n",
      "last_modified": "2021-09-03T16:21:16+02:00"
    },
    {
      "path": "test.html",
      "title": "Testing",
      "author": [],
      "contents": "\n\n\nCO2 %>% \n    head() %>% \n    test_tables()\n\n\n\n.tabwid table{\n  border-collapse:collapse;\n  line-height:1;\n  margin-left:auto;\n  margin-right:auto;\n  border-width: 0;\n  display: table;\n  margin-top: 1.275em;\n  margin-bottom: 1.275em;\n  border-spacing: 0;\n  border-color: transparent;\n}\n.tabwid_left table{\n  margin-left:0;\n}\n.tabwid_right table{\n  margin-right:0;\n}\n.tabwid td {\n    padding: 0;\n}\n.tabwid a {\n  text-decoration: none;\n}\n.tabwid thead {\n    background-color: transparent;\n}\n.tabwid tfoot {\n    background-color: transparent;\n}\n.tabwid table tr {\nbackground-color: transparent;\n}\n.cl-35f19b1c{border-collapse:collapse;}.cl-35e3b3a8{font-family:'DejaVu Sans';font-size:11pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(255, 255, 255, 1.00);background-color:transparent;}.cl-35e3b42a{font-family:'DejaVu Sans';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-35e3d0d6{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-35e3d130{margin:0;text-align:right;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-35e7f120{width:54pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-35e7f184{width:54pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}PlantTypeTreatmentconcuptakeQn1Quebecnonchilled9516.0Qn1Quebecnonchilled17530.4Qn1Quebecnonchilled25034.8Qn1Quebecnonchilled35037.2Qn1Quebecnonchilled50035.3Qn1Quebecnonchilled67539.2\n\nvar dest = document.getElementById(\"60a4d608-f5bb-4b7d-a692-625b156edeeb\");\nvar template = document.getElementById(\"539670f4-7e19-4853-8c43-47d8d2fb079f\");\nvar caption = template.content.querySelector(\"caption\");\nif(caption) {\n  caption.style.cssText = \"display:block;text-align:center;\";\n  var newcapt = document.createElement(\"p\");\n  newcapt.appendChild(caption)\n  dest.parentNode.insertBefore(newcapt, dest.previousSibling);\n}\nvar fantome = dest.attachShadow({mode: 'open'});\nvar templateContent = template.content;\nfantome.appendChild(templateContent);\n\nfor (i in 1) {\n    CO2 %>%\n        head() %>%\n        test_tables()\n}\n    \nfor (i in 1) {\n    CO2 %>%\n        head() %>%\n        test_tables() %>% \n        print()\n}\n    \nCO2 %>%\n    head() %>%\n    test_tables(test_ft = TRUE) \n\n\n\n.tabwid table{\n  border-collapse:collapse;\n  line-height:1;\n  margin-left:auto;\n  margin-right:auto;\n  border-width: 0;\n  display: table;\n  margin-top: 1.275em;\n  margin-bottom: 1.275em;\n  border-spacing: 0;\n  border-color: transparent;\n}\n.tabwid_left table{\n  margin-left:0;\n}\n.tabwid_right table{\n  margin-right:0;\n}\n.tabwid td {\n    padding: 0;\n}\n.tabwid a {\n  text-decoration: none;\n}\n.tabwid thead {\n    background-color: transparent;\n}\n.tabwid tfoot {\n    background-color: transparent;\n}\n.tabwid table tr {\nbackground-color: transparent;\n}\n.cl-3630ba90{border-collapse:collapse;}.cl-3628a26a{font-family:'DejaVu Sans';font-size:11pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(255, 255, 255, 1.00);background-color:transparent;}.cl-3628a2ba{font-family:'DejaVu Sans';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-3628b688{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-3628b6c4{margin:0;text-align:right;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-3628f97c{width:54pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-3628f9a4{width:54pt;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-3628f9b8{width:54pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-3628f9ea{width:54pt;background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}PlantTypeTreatmentconcuptakeQn1Quebecnonchilled9516.0Qn1Quebecnonchilled17530.4Qn1Quebecnonchilled25034.8Qn1Quebecnonchilled35037.2Qn1Quebecnonchilled50035.3Qn1Quebecnonchilled67539.2\n\nvar dest = document.getElementById(\"fe440beb-e003-4d2f-bbde-0c3831b2602c\");\nvar template = document.getElementById(\"d51cc8f2-7c7a-434b-81aa-bb85b4de41d4\");\nvar caption = template.content.querySelector(\"caption\");\nif(caption) {\n  caption.style.cssText = \"display:block;text-align:center;\";\n  var newcapt = document.createElement(\"p\");\n  newcapt.appendChild(caption)\n  dest.parentNode.insertBefore(newcapt, dest.previousSibling);\n}\nvar fantome = dest.attachShadow({mode: 'open'});\nvar templateContent = template.content;\nfantome.appendChild(templateContent);\n\nCO2 %>%\n    head() %>%\n    test_tables(test_gt = TRUE)\n\n\n\nhtml {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;\n}\n\n#hvajihvihm .gt_table {\n  display: table;\n  border-collapse: collapse;\n  margin-left: auto;\n  margin-right: auto;\n  color: #333333;\n  font-size: 16px;\n  font-weight: normal;\n  font-style: normal;\n  background-color: #FFFFFF;\n  width: auto;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #A8A8A8;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #A8A8A8;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n}\n\n#hvajihvihm .gt_heading {\n  background-color: #FFFFFF;\n  text-align: center;\n  border-bottom-color: #FFFFFF;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#hvajihvihm .gt_title {\n  color: #333333;\n  font-size: 125%;\n  font-weight: initial;\n  padding-top: 4px;\n  padding-bottom: 4px;\n  border-bottom-color: #FFFFFF;\n  border-bottom-width: 0;\n}\n\n#hvajihvihm .gt_subtitle {\n  color: #333333;\n  font-size: 85%;\n  font-weight: initial;\n  padding-top: 0;\n  padding-bottom: 6px;\n  border-top-color: #FFFFFF;\n  border-top-width: 0;\n}\n\n#hvajihvihm .gt_bottom_border {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#hvajihvihm .gt_col_headings {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n}\n\n#hvajihvihm .gt_col_heading {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 6px;\n  padding-left: 5px;\n  padding-right: 5px;\n  overflow-x: hidden;\n}\n\n#hvajihvihm .gt_column_spanner_outer {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: normal;\n  text-transform: inherit;\n  padding-top: 0;\n  padding-bottom: 0;\n  padding-left: 4px;\n  padding-right: 4px;\n}\n\n#hvajihvihm .gt_column_spanner_outer:first-child {\n  padding-left: 0;\n}\n\n#hvajihvihm .gt_column_spanner_outer:last-child {\n  padding-right: 0;\n}\n\n#hvajihvihm .gt_column_spanner {\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: bottom;\n  padding-top: 5px;\n  padding-bottom: 5px;\n  overflow-x: hidden;\n  display: inline-block;\n  width: 100%;\n}\n\n#hvajihvihm .gt_group_heading {\n  padding: 8px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#hvajihvihm .gt_empty_group_heading {\n  padding: 0.5px;\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  vertical-align: middle;\n}\n\n#hvajihvihm .gt_from_md > :first-child {\n  margin-top: 0;\n}\n\n#hvajihvihm .gt_from_md > :last-child {\n  margin-bottom: 0;\n}\n\n#hvajihvihm .gt_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  margin: 10px;\n  border-top-style: solid;\n  border-top-width: 1px;\n  border-top-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 1px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 1px;\n  border-right-color: #D3D3D3;\n  vertical-align: middle;\n  overflow-x: hidden;\n}\n\n#hvajihvihm .gt_stub {\n  color: #333333;\n  background-color: #FFFFFF;\n  font-size: 100%;\n  font-weight: initial;\n  text-transform: inherit;\n  border-right-style: solid;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n  padding-left: 12px;\n}\n\n#hvajihvihm .gt_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#hvajihvihm .gt_first_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n}\n\n#hvajihvihm .gt_grand_summary_row {\n  color: #333333;\n  background-color: #FFFFFF;\n  text-transform: inherit;\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n}\n\n#hvajihvihm .gt_first_grand_summary_row {\n  padding-top: 8px;\n  padding-bottom: 8px;\n  padding-left: 5px;\n  padding-right: 5px;\n  border-top-style: double;\n  border-top-width: 6px;\n  border-top-color: #D3D3D3;\n}\n\n#hvajihvihm .gt_striped {\n  background-color: rgba(128, 128, 128, 0.05);\n}\n\n#hvajihvihm .gt_table_body {\n  border-top-style: solid;\n  border-top-width: 2px;\n  border-top-color: #D3D3D3;\n  border-bottom-style: solid;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n}\n\n#hvajihvihm .gt_footnotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#hvajihvihm .gt_footnote {\n  margin: 0px;\n  font-size: 90%;\n  padding: 4px;\n}\n\n#hvajihvihm .gt_sourcenotes {\n  color: #333333;\n  background-color: #FFFFFF;\n  border-bottom-style: none;\n  border-bottom-width: 2px;\n  border-bottom-color: #D3D3D3;\n  border-left-style: none;\n  border-left-width: 2px;\n  border-left-color: #D3D3D3;\n  border-right-style: none;\n  border-right-width: 2px;\n  border-right-color: #D3D3D3;\n}\n\n#hvajihvihm .gt_sourcenote {\n  font-size: 90%;\n  padding: 4px;\n}\n\n#hvajihvihm .gt_left {\n  text-align: left;\n}\n\n#hvajihvihm .gt_center {\n  text-align: center;\n}\n\n#hvajihvihm .gt_right {\n  text-align: right;\n  font-variant-numeric: tabular-nums;\n}\n\n#hvajihvihm .gt_font_normal {\n  font-weight: normal;\n}\n\n#hvajihvihm .gt_font_bold {\n  font-weight: bold;\n}\n\n#hvajihvihm .gt_font_italic {\n  font-style: italic;\n}\n\n#hvajihvihm .gt_super {\n  font-size: 65%;\n}\n\n#hvajihvihm .gt_footnote_marks {\n  font-style: italic;\n  font-weight: normal;\n  font-size: 65%;\n}\nPlant\n      Type\n      Treatment\n      conc\n      uptake\n    Qn1\nQuebec\nnonchilled\n95\n16.0Qn1\nQuebec\nnonchilled\n175\n30.4Qn1\nQuebec\nnonchilled\n250\n34.8Qn1\nQuebec\nnonchilled\n350\n37.2Qn1\nQuebec\nnonchilled\n500\n35.3Qn1\nQuebec\nnonchilled\n675\n39.2\n\n\n\n\n",
      "last_modified": "2021-09-03T16:21:22+02:00"
    }
  ],
  "collections": []
}
